Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - levodopa, benserazide hydrochloride - hard capsule - levodopa 50 milligram(s) ; benserazide hydrochloride 12.5 milligram(s) - anti-parkinson drugs

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

roche (malaysia) sdn. bhd. - benserazide hydrochloride; levodopa -

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - benserazide hydrochloride 28.5mg equivalent to to 25 mg benserazide base; levodopa 100mg;   - capsule - 125 mg - active: benserazide hydrochloride 28.5mg equivalent to to 25 mg benserazide base levodopa 100mg   excipient: gelatin indigo carmine iron oxide red magnesium stearate microcrystalline cellulose povidone purified talc titanium dioxide - madopar is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism.

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base; levodopa 50mg;   - capsule - 62.5 mg - active: benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base levodopa 50mg   excipient: gelatin indigo carmine iron oxide black magnesium stearate mannitol microcrystalline cellulose povidone purified talc titanium dioxide - madopar is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism.

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base; levodopa 50mg;   - dispersible tablet - 62.5 mg - active: benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base levodopa 50mg   excipient: citric acid magnesium stearate maize starch microcrystalline cellulose - madopar rapid is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism. madopar rapid is a formulation which is suitable for patients with dysphagia (difficulties in swallowing) or who require a formulation with a more rapid onset of action, e.g. patients suffering from early morning and afternoon akinesia, or who exhibit "delayed on" or "wearing off" phenomena.

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - benserazide hydrochloride 28.5mg equivalent to to 25 mg benserazide base; levodopa 100mg;   - modified release capsule - 125 mg - active: benserazide hydrochloride 28.5mg equivalent to to 25 mg benserazide base levodopa 100mg   excipient: calcium hydrogen phosphate dihydrate gelatin hydrogenated vegetable oil hypromellose indigo carmine iron oxide yellow magnesium stearate mannitol povidone purified talc titanium dioxide - madopar hbs is indicated for patients presenting with all types of fluctuation in response, especially those related to fluctuations in plasma levels (i.e. "peak dose dyskinesia" and "end of dose deterioration") and for better control of nocturnal symptoms

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

roche (malaysia) sdn. bhd. - levodopa; benserazide hydrochloride -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

roche (malaysia) sdn. bhd. - levodopa; benserazide hydrochloride -

Ireland - English - HPRA (Health Products Regulatory Authority)

roche products (ireland) ltd - levodopa; benserazide - capsule, hard - 200 mg/50 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor

Ireland - English - HPRA (Health Products Regulatory Authority)

roche products (ireland) ltd - levodopa; benserazide - dispersible tablet - 50 mg/12.5 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor